Ph.D. Hanspeter ROTTENSTEINER Head, Research Gene Therapy EU, Shire Austria GmbH, Orth an der Donau
CV
| 1998 | Ph.D. in Biochemistry, University of Vienna |
| 1999-2002 | Postdoctoral Research, Freie Universität Berlin |
| 2002 | Assistant Professor, Ruhr-Universität Bochum |
| 2003-2007 | Professor in Physiological Chemistry, Bochum |
| 2007-2014 | Head of Recombinant Products, Global Research, Baxter, Vienna |
| 2014-2016 | Research Gene Therapy, Baxalta Innovations, Vienna |
| since 2016 | Head, Research Gene Therapy EU, Shire Austria GmbH, Orth an der Donau |
Mitgliedschaften
| American Society for Gene and Cell Therapy |
Publikationen
| Weber A, Engelmaier A, Voelkel D, Pachlinger R, Scheiflinger F, Monahan PE, Rottensteiner H.: "Development of methods for the selective measurement of the single amino acid exchange variant coagulation factor IX Padua." Mol Ther Methods Clin Dev., 2018 | |
| Verhenne S, Vandeputte N, Pareyn I, Izsvák Z, Rottensteiner H, Deckmyn H, De Meyer SF, Vanhoorelbeke K.: "Long-term prevention of congenital thrombotic thrombocytopenic purpura in ADAMTS13 knockout mice by sleeping beauty transposon-mediated gene therapy." Arterioscler Thromb Vasc Biol., 2017 | |
| Plaimauer B, Schiviz A, Kaufmann S, Höllriegl W, Rottensteiner H, Scheiflinger F.: "Neutralization of inhibitory antibodies and restoration of therapeutic ADAMTS-13 activity levels in inhibitor-treated rats by the use of defined doses of recombinant ADAMTS-13.", J Thromb Haemost., 2015 | |
| Grillberger R, Casina VC, Turecek PL, Zheng XL, Rottensteiner H, Scheiflinger F.: "Anti-ADAMTS13 IgG autoantibodies present in healthy individuals share linear epitopes with those in patients with thrombotic thrombocytopenic purpura.", Haematologica., 2014 |
